In human ILC210s from patients with systemic sclerosis (SSc), treatment with TGF-β dramatically decreased the production of IL-10 and reduced KLRG1 expression, an ILC2 surface marker found to be required for IL-10 production (29, 31, 32). This evidence concerns the gene TGFB1 and systemic sclerosis.